Evaluation of inflammatory acquired demyelinating syndromes in children: a single-center experience.
Acquired demyelinating syndromes
Acute disseminated encephalomyelitis
Childhood
MRI
Multiple sclerosis
Journal
Acta neurologica Belgica
ISSN: 2240-2993
Titre abrégé: Acta Neurol Belg
Pays: Italy
ID NLM: 0247035
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
10
02
2021
accepted:
03
05
2021
pubmed:
12
5
2021
medline:
2
12
2022
entrez:
11
5
2021
Statut:
ppublish
Résumé
To evaluate the clinical and neuroimaging features of pediatric acquired demyelinating syndromes (ADS) in a tertiary pediatric neurology clinic in Turkey. All children diagnosed with any subset of ADS between 2013 and 2018 were included in this retrospective cohort study. Forty-two patients (21 female) with a median follow-up period of 30 months were included. The median age of the patients at disease onset was 11 years (range 1.5-17 years). The most common pediatric ADS categories according to the International pediatric Multiple Sclerosis Study Group consensus classification criteria were acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS), each of which seen in 15 patients, followed by clinically isolated syndrome (CIS) (n = 11) and Neuromyelitis Optica Spectrum Disorder (NMOSD) (n = 1). At the first clinical event, children with ADEM significantly differed from the children affected by MS and CIS in terms of the following parameters: median age at onset (7 vs. 13.5 and 14.5 years; p < 0.001), encephalopathy (93.3 vs 0% and 0%; p < 0.001), and basal ganglia/thalamus lesions (73.3 vs 9.1% and 9.1%; p < 0.001). The frequency of seizure and pleocytosis were higher in ADEM group than MS group (p < 0.05), whereas oligoclonal bands (p < 0.001) and periventricular white matter lesions (p < 0.01) were more frequently observed in MS patients. Rituximab was used with great success in the prevention of relapses in 3 patients: NMOSD (n = 1), MS (n = 1) and ADEM followed by recurrent optic neuritis (n = 1). Our results define the longitudinal disease course of various ADS categories in a single referral center. In addition, this study compares various clinical, laboratory and neuroimaging features between these ADS categories.
Identifiants
pubmed: 33973168
doi: 10.1007/s13760-021-01703-4
pii: 10.1007/s13760-021-01703-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1485-1491Informations de copyright
© 2021. Belgian Neurological Society.
Références
Banwell B, Kennedy J, Sadovnick D et al (2009) Incidence of acquired demyelination of the CNS in Canadian children. Neurology 72:232–239
doi: 10.1212/01.wnl.0000339482.84392.bd
pubmed: 19153370
Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF et al (2012) Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol 259:1929–1935
doi: 10.1007/s00415-012-6441-6
pubmed: 22349866
pmcid: 3432787
Langer-Gould A, Zhang JL, Chung J et al (2011) Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology 77:1143–1148
doi: 10.1212/WNL.0b013e31822facdd
pubmed: 21865580
pmcid: 3265045
Krupp LB, Tardieu M, Amato MP et al (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19:1261–1267
doi: 10.1177/1352458513484547
pubmed: 23572237
Waldman A, Ghezzi A, Bar-Or A et al (2014) Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol 13:936–948
doi: 10.1016/S1474-4422(14)70093-6
pubmed: 25142460
pmcid: 4443918
Banwell B, Bar-Or A, Arnold DL et al (2011) Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 10:436–445
doi: 10.1016/S1474-4422(11)70045-X
pubmed: 21459044
Ness JM, Chabas D, Sadovnick AD et al (2007) Clinical features of children and adolescents with multiple sclerosis. Neurology 68:S37-45
doi: 10.1212/01.wnl.0000259447.77476.a9
pubmed: 17438237
Tenembaum S, Chitnis T, Ness J et al (2007) Acute disseminated encephalomyelitis. Neurology 68:S23-36
doi: 10.1212/01.wnl.0000259404.51352.7f
pubmed: 17438235
Schwarz S, Mohr A, Knauth M et al (2001) Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 56:1313–1318
doi: 10.1212/WNL.56.10.1313
pubmed: 11376180
Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189
doi: 10.1212/WNL.0000000000001729
pubmed: 26092914
pmcid: 4515040
Makhani N, Lebrun C, Siva A et al (2017) Radiologically isolated syndrome in children. Neurol Neuroimmunol Neuroinflamm 4:e395
doi: 10.1212/NXI.0000000000000395
pubmed: 28959703
pmcid: 5614726
Yılmaz Ü, Anlar B, Gücüyener K et al (2017) Characteristics of pediatric multiple sclerosis: the Turkish pediatric multiple sclerosis database. Eur J Paediatr Neurol 21:864–872
doi: 10.1016/j.ejpn.2017.06.004
pubmed: 28694135
Simone IL, Carrara D, Tortorella C et al (2002) Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 59:1922–1928
doi: 10.1212/01.WNL.0000036907.37650.8E
pubmed: 12499484
Atzori M, Battistella PA, Perini P et al (2009) Clinical and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in pediatric patients: a single centre prospective study. Mult Scler 15:363–370
doi: 10.1177/1352458508098562
pubmed: 18987105
Pohl D, Hennemuth I, Von Kries R, Hanefeld F (2007) Paediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey. Eur J Pediatr 166:405–412
doi: 10.1007/s00431-006-0249-2
pubmed: 17219129
Yamaguchi Y, Torisu H, Kira R et al (2016) A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 87:2006–2015
doi: 10.1212/WNL.0000000000003318
pubmed: 27742816
pmcid: 5109945
Dale RC, de Sousa C, Chong WK et al (2000) Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123(Pt 12):2407–2422
doi: 10.1093/brain/123.12.2407
pubmed: 11099444
Özkale Y, Özkale M, Demir E, Alehan F (2012) Acute disseminated encephalomyelitis associated with Influenza A H1N1 infection. Pediatr Neurol 47:62–64
doi: 10.1016/j.pediatrneurol.2012.03.019
pubmed: 22704021
pmcid: 7127454
Stonehouse M, Gupte G, Wassmer E, Whitehouse WP (2003) Acute disseminated encephalomyelitis: recognition in the hands of general paediatricians. Arch Dis Child 88:122–124
doi: 10.1136/adc.88.2.122
pubmed: 12538312
pmcid: 1719460
Gudbjornsson BT, Haraldsson Á, Einarsdóttir H, Thorarensen Ó (2015) Nationwide incidence of acquired central nervous system demyelination in Icelandic children. Pediatr Neurol 53:503–507
doi: 10.1016/j.pediatrneurol.2015.08.020
pubmed: 26463471
Öztürk Z, Yllmaz Ü, Konuśkan B et al (2018) Multiple sclerosis with onset younger than 10 years in Turkey. Neuropediatrics 49:51–58
doi: 10.1055/s-0037-1608776
pubmed: 29183093
Erol I, Özkale Y, Alkan Ö, Alehan F (2013) Acute disseminated encephalomyelitis in children and adolescents: a single center experience. Pediatr Neurol 49:266–273
doi: 10.1016/j.pediatrneurol.2013.03.021
pubmed: 23849604
pmcid: 7127658
Durmus H, Kurtuncu M, Tuzun E et al (2013) Comparative clinical characteristics of early- and adult-onset multiple sclerosis patients with seizures. Acta Neurol Belg 113:421–426
doi: 10.1007/s13760-013-0210-x
pubmed: 23696071
Alper G, Heyman R, Wang L (2009) Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features. Dev Med Child Neurol 51:480–486
doi: 10.1111/j.1469-8749.2008.03136.x
pubmed: 19018840
Neuteboom RF, Boon M, Catsman Berrevoets CE et al (2008) Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology 71:967–973
doi: 10.1212/01.wnl.0000316193.89691.e1
pubmed: 18672475
Sponsler JL, Kendrick-Adey AC (2011) Seizures as a manifestation of multiple sclerosis. Epileptic Disord 13:401–410
doi: 10.1684/epd.2011.0468
pubmed: 22258045
Hacohen Y, Wong YY, Lechner C et al (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody–Associated disease. JAMA Neurol 75:478–487
doi: 10.1001/jamaneurol.2017.4601
pubmed: 29305608
pmcid: 5885190
Ramanathan S, O’grady GL, Malone S, et al (2019) Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children. Dev Med Child Neurol 61:610–614
doi: 10.1111/dmcn.14032
pubmed: 30221764
Rossor T, Benetou C, Wright S et al (2020) Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. Mult Scler 26:333–342
doi: 10.1177/1352458518823486
pubmed: 30730236
Chitnis T, Tenembaum S, Banwell B et al (2012) Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 18:116–127
doi: 10.1177/1352458511430704
pubmed: 22146610
Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910
doi: 10.1056/NEJMoa044397
pubmed: 16510744
Ghezzi A, Moiola L, Pozzilli C et al (2015) Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol 15:174
doi: 10.1186/s12883-015-0433-y
pubmed: 26407848
pmcid: 4583752